⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

March 1, 2026ESMO rare cancers.Open Access

164P Complex symptomatic PN surgery in NF1: Outcomes and the necessity of subsequent selumetinib treatment

A. A. Tararykova A. Valiev Beniamin Yu. Bokhyan A. G. Salkov M. Khachaturov Z. Kumekhov E. Showa A. Konev

View Full Paper

Ask AI

Bookmark

Share

Implication

Uncovers the necessity for novel treatments in advanced CHS after surgery, indicating new directions for therapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tararykova et al. (2026) studied this question.

synapsesocial.com/papers/69b257bf96eeacc4fcec69ed https://doi.org/10.1016/j.esmorc.2026.100370

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1163P Robotic surgery in the management of gastric GISTOriginal Research · 2026
2165P Trabectedin or gemcitabine-based chemotherapy as second-line therapy for advanced leiomyosarcoma: An IPTW-adjusted analysisHuman Clinical Trial · 2026
3166P Early progression severely limits access to second-line therapy in recurrent/metastatic complex karyotype soft tissue sarcomas (CKSTS)Clinical Trial · 2026
4NFS-27. SELUMETINIB FOR SYMPTOMATIC, INOPERABLE PLEXIFORM NEUROFIBROMAS IN NEUROFIBROMATOSIS TYPE 1: A SINGLE-INSTITUTION EXPERIENCE2024 · 1 citations
5Efficacy and safety of anlotinib and sintilimab combined with GEMOX in advanced combined hepatocellular-cholangiocarcinoma (cHCC-CCA): A prospective phase II study.Early-Phase Clinical Trial · 2026